Ebastine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ebastine
Accession Number
DB11742
Type
Small Molecule
Groups
Approved, Investigational
Description

Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
TQD7Q784P1
CAS number
90729-43-4
Weight
Average: 469.6576
Monoisotopic: 469.298079497
Chemical Formula
C32H39NO2
InChI Key
MJJALKDDGIKVBE-UHFFFAOYSA-N
InChI
InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3
IUPAC Name
1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one
SMILES
CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Ebastine H1-Antihistamine ActionDrug action
Ebastine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Ebastine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Ebastine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Ebastine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Ebastine.Experimental, Illicit
AmiodaroneThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Amiodarone.Approved, Investigational
AmphetamineAmphetamine may decrease the sedative activities of Ebastine.Approved, Illicit, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Ebastine.Approved
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Ebastine.Approved, Illicit
Benzylpenicilloyl PolylysineEbastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Ebastine.Approved, Investigational
BrigatinibThe serum concentration of Ebastine can be decreased when it is combined with Brigatinib.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Brompheniramine.Approved
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ebastine.Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Ebastine.Illicit, Withdrawn
CinnarizineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Ciprofloxacin.Approved, Investigational
ClemastineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Clemastine.Approved, Investigational
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ebastine.Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Ebastine.Approved, Illicit
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Ebastine.Approved, Illicit
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ebastine.Approved, Investigational
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ebastine.Approved, Vet Approved
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ebastine.Approved
FluoxetineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Fluoxetine.Approved, Vet Approved
GepefrineGepefrine may decrease the sedative activities of Ebastine.Experimental
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ebastine.Approved, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Ebastine.Approved
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Ebastine.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ebastine.Approved, Investigational
IdelalisibThe serum concentration of Ebastine can be increased when it is combined with Idelalisib.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Ebastine.Approved
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Ebastine.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Ebastine.Approved, Investigational
LoratadineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Loratadine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Ebastine.Investigational
MephentermineMephentermine may decrease the sedative activities of Ebastine.Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Mepyramine.Approved, Vet Approved
MethamphetamineMethamphetamine may decrease the sedative activities of Ebastine.Approved, Illicit
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Ebastine.Experimental
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ebastine.Approved, Investigational
MidomafetamineMidomafetamine may decrease the sedative activities of Ebastine.Experimental, Illicit, Investigational
MMDAMMDA may decrease the sedative activities of Ebastine.Experimental, Illicit
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Moxifloxacin.Approved, Investigational
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Ebastine.Approved, Investigational
OndansetronThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Ondansetron.Approved
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Ebastine.Approved, Investigational
PheniramineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Pheniramine.Approved
PhenterminePhentermine may decrease the sedative activities of Ebastine.Approved, Illicit
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Ebastine.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Propafenone.Approved
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Ebastine.Approved
QuetiapineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Quetiapine.Approved
RibociclibThe serum concentration of Ebastine can be increased when it is combined with Ribociclib.Approved, Investigational
RitobegronRitobegron may decrease the sedative activities of Ebastine.Investigational
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ebastine.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ebastine.Approved
TerodilineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Terodiline.Experimental
Valproic AcidThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Ebastine.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0060159
PubChem Compound
3191
PubChem Substance
347828100
ChemSpider
3079
BindingDB
22873
ChEBI
31528
ChEMBL
CHEMBL305660
Wikipedia
Ebastine
ATC Codes
R06AX22 — Ebastine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentIrritable Bowel Syndrome (IBS)1
4CompletedTreatmentUrticarias1
4RecruitingTreatmentIrritable Bowel Syndrome (IBS)1
Not AvailableUnknown StatusTreatmentCoughing1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.47e-05 mg/mLALOGPS
logP6.89ALOGPS
logP6.96ChemAxon
logS-6.9ALOGPS
pKa (Strongest Acidic)16.45ChemAxon
pKa (Strongest Basic)8.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity145.38 m3·mol-1ChemAxon
Polarizability55.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0gi0-0930400000-a3b7001dd8bec489cf92

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Alkyl-phenylketones / Phenylbutylamines / Butyrophenones / Phenylpropanes / Benzylethers / Benzoyl derivatives / Aryl alkyl ketones / Piperidines / Gamma-amino ketones / Trialkylamines
show 5 more
Substituents
Diphenylmethane / Alkyl-phenylketone / Butyrophenone / Phenylbutylamine / Benzylether / Phenylketone / Phenylpropane / Benzoyl / Aryl alkyl ketone / Aryl ketone
show 18 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:43 / Updated on August 02, 2018 06:28